Evaluation of the therapeutic efficiency of the placenta mesenchymal stem cell-derived exosomes on the improvement of interstitial lung

Evaluation of the therapeutic efficiency of the placenta mesenchymal stem cell-derived exosomes on the improvement of interstitial lung disease symptoms in systemic sclerosis patients, a single-arm trial.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N184

Enrollment

Registered

2022-04-16

Start date

2022-04-18

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic sclerosis (scleroderma). Systemic sclerosis [scleroderma]

Interventions

In addition to standard treatment (cyclophosphamide and mycophenolate mofetil), the intervention group will receive exosomes derived from placenta mesenchymal stem cells in three sessions two weeks ap

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed consent American College of Rheumatology (ACR) and EULAR2013 diagnostic criteria for systemic sclerosis Intestinal lung disease confirmed by chest CT scan and lung function tests

Exclusion criteria

Exclusion criteria: Suffering from other autoimmune diseases Uncontrolled high blood pressure, diabetes, and other endocrine disorders Cardiovascular failure Chronic renal failure Hepatic impairment Depression Existence of life-threatening conflicts including severe platelet hemolysis below 40,000 Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Rate of pulmonary involvement. Timepoint: Before and after the intervention (4-6 weeks later). Method of measurement: Using CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDena Mohamadzadeh

Kermanshah University of Medical Sciences

denamohamadzadeh75@gmail.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026